Related Experiment Video
Updated: Apr 12, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory
Sara Steinmann1, Kristina Scheibe2, Katharina Erlenbach-Wuensch3
1Experimental Tumorpathology, Institute of Pathology, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Abstract:
The cytoskeleton-associated serine/threonine kinase death-associated protein kinase (DAPK) has been described as a cancer gene chameleon with functional antagonistic duality in a cell type and context specific manner. The broad range of interaction partners and substrates link DAPK to inflammatory processes especially in the gut. Herein we summarize our knowledge on the role of DAPK in different cell types that play a role under inflammatory conditions in the gut. Besides some promising experimental data suggesting DAPK as an interesting drug target in inflammatory bowel disease there are many open questions regarding direct evidence for a role of DAPK in intestinal inflammation.
Insights
Death-associated protein kinase (DAPK) impacts gut inflammation. While DAPK shows potential as an inflammatory bowel disease drug target, its direct role in intestinal inflammation requires further investigation.
Area of Science:
- Molecular biology
- Cell biology
- Gastroenterology
Background:
- Death-associated protein kinase (DAPK) is a serine/threonine kinase implicated in cancer.
- DAPK exhibits context-dependent functional duality.
- DAPK interacts with numerous proteins, linking it to inflammatory pathways, particularly in the gut.
Purpose of the Study:
- To review the role of DAPK in various cell types involved in gut inflammation.
- To assess the potential of DAPK as a therapeutic target for inflammatory bowel disease (IBD).
Main Methods:
- Literature review of studies investigating DAPK in gut inflammation.
- Analysis of experimental data on DAPK's function in relevant cell types.
Main Results:
- DAPK's involvement in inflammatory processes within the gut is suggested by its interaction partners.
- Experimental data indicates DAPK may be a viable drug target for IBD.
Conclusions:
- DAPK plays a role in gut inflammatory conditions.
- Further research is needed to establish direct evidence for DAPK's role in intestinal inflammation and its therapeutic potential in IBD.
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

